T
PBE icon

Thomaspartners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Thomaspartners’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-200
Closed -$6K – 181
2013
Q2 		$6K Buy
+200
New +$5.69K ﹤0.01% 187

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NCM
Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
PFG
Pacific Financial Group Bellevue, Washington $186M AUM 16.59% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.06B AUM 19.66% 1-Year Est. Return

Thomaspartners's PBE Position: Q3 2013 in Review

Thomaspartners sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2013, closing a stake of 200 shares — an estimated $6K sold.

Thomaspartners first reported a position in PBE in Q2 2013 and held it in 1 quarter. The position peaked at $6K in Q2 2013. 51 funds tracked by Wall St. Rank hold PBE as of Q3 2013.

  • Thomaspartners reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2013 after selling out during the quarter.
  • Thomaspartners sold 200 Invesco Biotechnology & Genome ETF shares in Q3 2013, an estimated $6K.
  • Thomaspartners first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and held it in 1 quarter.
  • Thomaspartners's Invesco Biotechnology & Genome ETF position peaked at $6K in Q2 2013.
  • 51 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2013.

Based on Thomaspartners's 13F filing for Q3 2013, filed 14 Nov 2013.